Floatz logo

Abobotulinumtoxina

Compartment Syndrome

Explore 1 assets in Compartment Syndrome →
Floatz Rating
B56/100
Confidence
Indicative
v0.2
Sponsor
Emory University
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05466539CT.gov
Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Compartment Syndrome

AssetSponsorPhaseRating
Abobotulinumtoxina (this asset)Emory UniversityApprovedB · 56

Other indications for Abobotulinumtoxina

IndicationSponsorPhaseRating
Spastic Cerebral Palsy—P2CC · 47
Plantar Fasciitis—P2CC · 47
Multiple Sclerosis—P3CC · 46

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Abobotulinumtoxina in Compartment Syndrome. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/abobotulinumtoxina-compartment-syndrome

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →